Analyzing brain tumors using advanced imaging techniques
Official title: Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis
Run by Tata Memorial Centre · NCT06036381 · Data updated 2026-11-12
This study is testing how advanced imaging techniques can help doctors better understand and classify gliomas, a type of brain tumor, by looking at past medical images from patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Tata Memorial Centre Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Mumbai, Maharashtra) |
| Status | Recruiting |
| Started | February 15, 2024 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | April 9, 2025 |
| Trial ID | NCT06036381 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with glioma or glioma-mimicking pathology who have imaging available from Tata Memorial Centre between 2010 and 2022.
✕Probably not a fit
Patients whose imaging was conducted outside Tata Memorial Centre or those with significant image artifacts may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on gliomas, a type of primary brain tumor, by utilizing artificial intelligence and radiomic analysis of medical images such as MRI, CT, and PET scans. The research aims to identify abnormal tumor areas, classify gliomas based on prognosis, and assess treatment responses through retrospective analysis of imaging data collected from patients at Tata Memorial Centre between 2010 and 2022. By employing advanced image processing techniques, the study seeks to enhance the understanding of glioma characteristics and improve diagnostic accuracy.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and treatment strategies for patients with gliomas.
How similar studies have gone: Other studies utilizing radiomic analysis and artificial intelligence in glioma characterization have shown promising results, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with glioma or glioma-mimicking pathology with imaging available in TMC between January 2010 and December 2022. Exclusion Criteria: * Imaging done outside TMC. * Motion artifacts or other artifacts causing image degradation. * Size of tumor or region of interest \< 1 cm in the largest dimension
Where it's running
-
Tata Memorial Hospital
Mumbai, Maharashtra, India Recruiting
Study contacts
- Principal investigator: Dr. ARCHYA DASGUPTA, MD — Tata Memorial Hospital
- Study coordinator: Dr. ARCHYA DASGUPTA, MD
- Email: archya1010@gmail.com
- Phone: 022-24177000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.